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Abstract
TW-37 is a small molecule B cell lymphoma-2 (Bcl-2) homology 3 mimetic with potential anticancer activities.
However, the in vivo anti-cancer effect of TW-37 in human oral cancer has not been properly studied yet. Here,
we attempted to confirm antitumor activity of TW37 in human oral cancer. TW-37 significantly inhibited cell
proliferation and increased the number of dead cells in MC-3 and HSC-3 human oral cancer cell lines. TW-37
enhanced apoptosis of both cell lines evidenced by annexin V/propidium iodide double staining, sub-G1
population analysis and the detection of cleaved poly (ADP-ribose) polymerase and caspase-3. In addition, TW-37
markedly downregulated the expression of Bcl-2 protein, while not affecting Bcl-xL or myeloid cell leukemia-1. In
vivo, TW-37 inhibited tumor growth in a nude mice xenograft model without any significant liver and kidney
toxicities. Collectively, these data reveal that TW-37 may be a promising small molecule to inhibit human oral
cancer.
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Introduction
With a development of patient screening tools and a re-
search on pathways involved in tumorigenesis, anti-
cancer drug research was developed by converting from
chemotherapy inducing cytotoxic responses to target
therapy that interferes specific molecules associated with
tumorigenesis [1]. Induction of apoptosis by molecular
target-based drugs plays a critical role in cancer treat-
ment against various types of cancers [2–4]. The anti-
apoptotic Bcl-2 molecules including B-cell lymphoma
2 (Bcl-2) are key regulators of apoptosis by suppressing
the activation of proapoptotic Bcl-2 family [5] and
these proteins were often over-expressed in many
cancers [6, 7]. Recently, several studies showed that
small molecules exhibited anticancer activity by target-
ing Bcl-2 family which is associated with intrinsic
pathways of apoptosis [8, 9]. Thus, the development of
anti-apoptotic Bcl-2 inhibitors has important implica-
tions for cancer treatment and prevention.
TW-37 is a second-generation benzenesulphonyl deriva-
tive of gossypol isolated from cotton seeds and roots. It
was recently demonstrated that TW-37 attenuated the
activation of Bcl-2, Bcl-xL and myeloid cell leukemia-1
(Mcl-1) via directly binding to Bcl-2 homology 3 (BH3)
binding groove with high affinity, resulting in the induc-
tion of apoptosis [10, 11]. In the case reports of oral
cancer patients, anti-apoptotic Bcl-2 family proteins were
markedly increased in precancerous lesions suggesting
that they can act as oncoproteins for oral carcinogenesis
[12–14]. Previously, our group published that BH3
mimetics such as ABT-263 and ABT-737 exhibited
apoptosis-inducing potential in oral cancer [15–17].
Recently, we also showed the in vitro anti-cancer effects of
TW-37 in human oral cancer cell lines [18]. These suggest
that small molecule inhibitors targeting Bcl-2 family pro-
teins can be a promising drug candidate against human
oral cancer. To date, however, no study on the in vivo
effect of TW-37 in oral cancer has been conducted.
In the present study, we sought to identify in vitro and
in vivo anti-cancer activity of TW-37 in human oral cancer.
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Methods
Cell culture and treatment
The MC-3 mucoepidermoid carcinoma cell line was
kindly provided by prof. Wu Junzheng (Forth Military
Medical University, Xi’an, China) and HSC-3 oral
squamous cell carcinoma cell line was given by Prof.
Masanobu Shindoh from Hokkaido University (Hokkaido,
Japan). Cells were cultured in Dulbecco’s Modified Eagle
Medium/F12 supplemented with 10% heat inactivated
fetal bovine serum and antibiotics at 37 °C in a humidified
atmosphere 5% CO2. All experiments were performed
when the cells reached approximately 50~60% confluence.
TW-37 (ApexBio, Houston, TX, USA) was dissolved in di-
methyl sulfoxide (DMSO), aliquoted, and stored at −
20 °C. Final concentration of DMSO did not exceed 0.1%.
Trypan blue exclusion assay
The anti-proliferative effect of TW-37 was determined
with trypan blue solution (Gibco, Paisley, UK). The
number of viable cells, unstained with trypan blue (0.4%)
solution, was counted using a hemocytometer with a
light microscope.
Live/dead assay
The cytotoxicity of TW-37 was determined using a Live/
Dead Viability/Cytotoxicity assay kit (Life Technologies,
Grand Island, NY). The principle of this kit is that live
cells are distinguished by the presence of ubiquitous
intracellular esterase activity. Briefly, cells were stained
with 2 μM calcein-AM and 4 μM ethidium homodimer-1
and incubated for 30 min at room temperature (RT) ac-
cording to the manufacturer instructions. Cells were
then observed using a fluorescence microscopy (Leica
DMi8, Wetzlar, Germany).
Annexin V/PI double staining
Apoptosis was evaluated by double staining with annexin
V-fluorescein isothiocyanate (FITC) and propidium iodide
(PI), according manufacturer’s instructions of annexin V
apoptosis assay kit (BD Biosciences, Franklin Lakes, NJ,
USA). The stained cells were analyzed in fluorescence-
activated cell sorting (FACS) caliber (Becton-Dickinson)
and calculated with Flowjo software (Flowjo LLC, Ash-
land, OR, USA).
Cell cycle analysis
Cells were fixed with 70% ethanol overnight at 4 °C.
20 μg/mL (final concentration) of RNase A and PI
(P4170, Sigma-Aldrich) were added and then incubated
for 15 min at 37 °C. DNA contents were detected using
FACS caliber and the relative DNA content was and cal-
culated with FlowJo software.
Western blotting
After treatment, the cells were harvested, rinsed with
phosphate buffered saline (PBS), and then lysed with a
lysis buffer on ice. The total protein concentration was
measured using a DC Protein Assay Kit (BIO-RAD La-
boratories, Madison, WI, USA). The same amount of
protein was then loaded onto sodium dodecyl sulfate
polyacrylamide gel electrophoresis and transferred onto
an immunoblot polyvinylidene fluoride membranes. The
membrane was blocked for 2 h in 5% skim milk in tris-
buffered saline with Tween 20 and incubated with pri-
mary antibodies overnight at 4 °C and corresponding
horseradish peroxidase-conjugated secondary antibodies.
Antibodies against cleaved poly (ADP-ribose) polymer-
ase (PARP), cleaved caspase-3, Bcl-xL and Mcl-1 were
purchased from Cell Signaling Technology, Inc. (Char-
lottesville, VA, USA) and antibodies against Bcl-2 and β-
actin were obtained from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA). Chemiluminescence were de-
tected by SuperSignal West Pico Chemiluminescent
Substrate (Santa Cruz Biotechnology Inc.) and were cap-
tured by X-ray film or ImageQuant LAS 500 (GE
Healthcare Life Sciences, Piscataway, NJ, USA).
Nude mouse model of human tumor
Six-week-old Balb/c nu/nu male mice (NARA Biotech,
Pyeongtaek, Korea) were caged in a facility with a 12-h
light/dark cycle and allowed Teklad diet (2018s) and
water ad libitum. All mice were handled according to In-
stitutional Animal Care and Use Committee (IACUC)
guidelines approved by CHA University (IACUC ap-
proval number: 190077). HSC-3 cells were subcutane-
ously injected into the flanks of the mice and the mice
were then assigned randomly to two treatment groups
(four mice per group). About 10 days after incubation,
tumor-bearing mice were injected intraperitoneally with
either vehicle control (PBS) or TW37 (15 mg/kg/day) for
21 days (5 days per week). Tumor volume and was moni-
tored twice a week. Tumor volumes were measured
along the two diameter axes with calipers and the tumor
volumes were calculated using the equation volume = π/
6 × ([D + d]/2)3, where D and d are the larger and
smaller diameters, respectively. At the termination of the
experiment, mice were euthanized, tumors were re-
trieved to measure tumor weight.
Histopathological findings
Mouse organs (liver and kidneys) were fixed in 10%
neutral buffered formalin. Tissue sections were cut to a
thickness of 4 μm and stained with hematoxylin (Mayer’s,
Klinipath, Benelux) and eosin (Eosin Y, Klinipath,
Benelux). Histopathological changes were analyzed under
a Nikon Eclipse E800 microscope.
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Fig. 1 Effect of TW-37 on the viability in human oral cancer cell lines. MC-3 and HSC-3 cell lines were treated with DMSO or 5 μM of TW-37 for
48 h. a Cell viability (%) was assessed by trypan blue exclusion assay. The data shown in the graph represent the mean ± SD of triplicate
experiments. *, p < 0.05 compared with the control. b Cytotoxic effect of TW-37 was determined by Live/dead assay kit. Live cells (green
fluorescence) and dead cells (red fluorescence) were observed under a light microscope (magnification, × 200)
Fig. 2 Effect of TW-37 on apoptosis in human oral cancer cell lines. MC-3 and HSC-3 cell lines were treated with DMSO or 5 μM of TW-37 for 48 h. a
The number of apoptotic cells were determined by annexin V/PI double-staining. b Sub-G1 population was assessed by FACS analysis. The data shown
in the graphs represent the mean ± SD of triplicate experiments. *, p < 0.05 compared with the control
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Statistical analysis
For the in vitro study, ANOVA followed by Tukey’s post
hoc test were used to determine the significance
between the control and treatment groups. For the
in vivo study, statistical evaluation was performed using
the Mann-Whitney U test in SPSS because our data
were non-parametric. p value of < 0.05 was considered
significant (*).
Results
Tw-37 inhibits cell growth and viability in MC-3 and HSC-
3 human oral cancer cell lines
To explore the anti-proliferative effects of TW-37, MC-3
and HSC-3 cell lines were treated with TW-37 (5 μM)
for 48 h and cell growth was evaluated by a trypan blue
exclusion assay. Treatment with TW-37 significantly re-
duced cell proliferation by more than 50% compared
with the control (Fig. 1a). Next, we performed a two-
color fluorescence assay, which detects esterase activity
or cell permeability to confirm the cytotoxic effect of
TW-37 in both cell lines. As shown in Fig. 1b, the num-
ber of red fluorescence-positive cells by EthD-1 was
markedly increased. These results suggest that TW-37
may have anti-proliferative effect by inhibiting cell
growth and inducing cell death in human oral cancer
cell lines.
TW-37 increased the apoptotic cell population in human
oral cancer cell lines
To date, many researches revealed that TW-37 can in-
duce apoptotic response in various types of cancer cell
lines [16–19]. Thus, we performed annexin V/PI staining
and DAPI staining to evaluate the effect of TW-37 in
MC-3 and HSC-3 cell lines. The results showed that the
Fig. 3 Effect of TW-37 on Bcl-2 family-related apoptosis in human oral cancer cells. a and b the apoptosis related proteins (c-PARP and c-
caspase3) and anti-apoptotic Bcl-2 family proteins (Bcl-2, Bcl-xL, and Mcl-1) were detected using western blot analysis. β-actin was used as a
loading control. The data shown in the graphs represent the mean ± SD of triplicate experiments. *, p < 0.05 compared with the control
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percentage of apoptotic cell population (annexin V-
FITC-positive) in TW-37- treated group (25.38% for
MC-3 cells and 37.00% for HSC-3 cells) dramatically in-
creased compared with in control-treated group (8.74%
for MC-3 cells and 13.54% for HSC-3 cells) (Fig. 2a). We
further performed cell cycle analysis to determine the
sub-G1 population. As shown in Fig. 2b, the appearance
of sub-G1 peak (apoptotic feature) was significantly in-
duced by TW-37 (7.53% for MC-3 cells and 13.70% for
HSC-3 cells) compared with control (0.64% for MC-3
cells and 2.15% for HSC-3 cells). These results suggest
that TW-37 can induce morphological changes of apop-
totic body and fraction of DNA associated with apop-
tosis in human oral cancer cells.
TW-37 induced the apoptosis by downregulating Bcl-2
protein in human oral cancer cells
To ascertain TW-37-mediated apoptosis in human oral
cancer cell lines, we did western blotting using anti-
bodies against cleaved caspase3 and cleaved PARP,
which are known as apoptosis-related protein markers.
As shown in Fig. 3a, TW-37 treatment effectively in-
duced apoptotic cell death, as evidenced by the cleavages
of caspase 3 and PARP. Because TW-37 is one of BH-3
mimetics that are able to target anti-apoptotic Bcl-2
family proteins, we investigated whether TW-37 affects
those proteins such as Bcl-2, Bcl-xL, and Mcl-1. As
shown in Fig. 3b, Bcl-2 expression was significantly re-
duced by TW-37 while not affecting Bcl-xL and Mcl-1
protein. These results suggest that TW-37-induced
apoptosis may be related with the downregulation of
Bcl-2 protein.
TW-37 suppresses tumor growth in a tumor xenograft
model without any toxicity
To evaluate the efficacy of in vivo antitumor activity of
TW-37, we used a xenograft mice model by subcutane-
ously injection of HSC-3 cells into the flank of athymic
nude mice. As shown in Fig. 4a and b, TW-37 treat-
ment significantly decreased tumor volume on day 16
after the treatment. Consistent with this, the average
of tumor weight was reduced at a very slight trend
toward significance (Fig. 4c). Next, to investigate the
effects of TW-37 on in vivo biocompatibility, we mea-
sured the body and organs (liver and kidneys) weights.
TW-37 treatment did not affect significant changes of
body and organs weight (Fig. 5). In addition, histopath-
ologic evaluation of liver and kidney did not show any
pathological differences between the control- and TW-
37-treated mice (Fig. 6). These results suggest that
TW-37 administration suppresses tumor growth in our
mouse xenograft model of human oral tumor without
causing histopathological toxicity.
Discussion
Apoptosis is the most important physiological cell death
and is tightly regulated by pro- and antiapoptotic cas-
cades during development and aging. Homeostatic state
between apoptosis and cell division is essential for main-
taining cell populations in normal tissues. Thus, the
dysregulation of apoptosis can cause many human dis-
eases including cancer [19, 20]. A number of small
molecule inhibitors were previously designed to induce
apoptosis against cancers by targeting anti-apoptotic
Bcl-2 proteins characterized into groups based on their
structure and function [21]. For instance, venetoclax
Fig. 4 Effect of TW-37 on tumor growth in a xenograft mice model. Balb/c nude baring HSC-3 cells were treated with vehicle control (PBS) or
TW-37 (15 mg/kg/day) for 21 days (n = 4/group). a The photograph of tumor tissues. Tumor volume (b) and tumor weight (c) were measured. The
values are presented as mean ± SEM of 4 mice per group. *, p < 0.05 compared with the control
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(ABT-199/GDC-0199) is typical Bcl-2 inhibitor that
plays a role as BH3 mimic for the treatment of Bcl-2-
dependent hematological cancers [22]. Lin et al. [23] also
reported that ABT-263 induced cell cycle arrest, apop-
tosis and autophagy in human esophageal cancer cells.
In 2006, TW-37 was developed as a small molecule in-
hibitor of Bcl-2, Bcl-XL, and Mcl-1 and was shown to
have anti-cancer activity in lymphoma cells [24]. Several
researches showed that TW-37 stimulated apoptotic cell
death and changed cytotoxicity towards the drug-
sensitive and resistance in nasopharyngeal carcinoma,
colorectal cancer, ovarian cancer, and neuroblastoma
[25–28]. In this study, we investigated the anti-cancer
activity of TW-37 in MC-3 and HSC-3 human oral can-
cer cell lines. Consistent with the discovery of others,
TW-37 significantly exhibited anti-cancer activity in
human oral cancer cells via the induction of apoptosis.
In addition, we found that TW-37 specifically affected
Bcl-2 proteins suggesting that Bcl-2 is a major molecule
target for TW-37-induced apoptosis as expected. In con-
trast, our group recently published that lower concentra-
tion (1.25 μM) of TW-37 did not inhibit cell growth and
Fig. 6 Histopathological findings of liver (a) and kidney (b). (magnification, × 100)
Fig. 5 Effect of TW-37 on body and organs weight. Body weight (a) and weights of liver and kidney (b) were measured after sacrifice. Each graph
represents mean ± SEM of 4 mice per group
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induce apoptosis in MC-3 cells [18]. It means that the
findings of the current study do not support our previ-
ous research. A possible explanation for this might be
that only higher concentration of TW-37 may be associ-
ated with Bcl-2 protein during its apoptotic activity in
MC-3 cells. However, future investigations might explain
why only higher concentration of TW-37 may act as a
Bcl-2 inhibitor.
Several reports have shown that TW-37 treatment sig-
nificantly inhibited tumor growth in vivo without any
toxicity or any loss of body weight [25, 29]. However,
there have been no studies using experimental animals
for human oral cancer. In the present study, we found
that TW-37 also suppressed tumor growth without any
body weight loss and any histopathologic changes of
both liver and kidney tissues (Figs. 4, 5 and 6). These
data broadly support the work of other studies. How-
ever, one unanticipated finding was that it was only sig-
nificantly effective until the day 16 of TW-37 material
treatment and its antitumor activity was not significant
at the time of sacrifice (Fig. 4b). It seems possible that
these results may be due to the acquisition of drug re-
sistance to TW-37 in MC-3 cells. However, we still need
to determine how MC3 cells acquire drug tolerance in
the early time. Innate or acquired resistance to chemo-
therapy is a major cause of treatment failure in cancer pa-
tients. Despite BH3 mimetics targeting members of Bcl-2
family have received much attention for the recent success
of cancer treatments, particularly hematological malignan-
cies, single drug BH3 mimetic therapy also has limited
effectiveness [30, 31]. Actually, there are such previous
studies showing that BH3 mimetics had drug resistances
by compensatory activity of Mcl-1 for the inhibition of
Bcl-2/Bcl-xL and Mcl-1 activation sensitized cancer cells
to BH3 mimetics [32–35]. These suggest that the combin-
ational therapeutic strategy could directly activate the cell
death mechanism to overcome its limitation. Thus, it is
worthwhile to clarify it in future studies although combin-
ation strategy with TW-37 remains unclear.
Conclusions
The study presented here showed the anti-cancer effects
of TW37 in human oral cancer cell line and nude mice
tumor xenograft model. Our findings provide a strong
possibility of TW-37 as a potential antitumor agent for
oral cancer despite several important questions still need
to be explained.
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